Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277. Page 271, Results, Base Case, second line from the bottom, the text “€ 15,134” should read “€ 151,434”. The authors apologize for this error. Read the original article

Detalhes bibliográficos

Principais autores:	Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyagüez I, Brockbank J, Iglesias T, Llinares J, Sierra J
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Dove Medical Press 2021-07-01
coleção:	ClinicoEconomics and Outcomes Research
Assuntos:	cost-effectiveness gemtuzumab ozogamicin acute myeloid leukaemia spain
Acesso em linha:	https://www.dovepress.com/corrigendum-cost-effectiveness-analysis-of-gemtuzumab-ozogamicin-for-f-peer-reviewed-fulltext-article-CEOR
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!